Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
14.80
-0.26 (-1.73%)
Aug 27, 2026, 10:11 AM EDT - Market open
Adlai Nortye Revenue
Adlai Nortye had revenue of $13.06M in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to $18.06M. In the year 2025, Adlai Nortye had annual revenue of $5.00M.
Revenue (ttm)
$18.06M
Revenue Growth
n/a
P/S Ratio
53.71
Revenue / Employee
$165,651
Employees
109
Market Cap
953.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 45.73M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ANL News
- 12 days ago - Adlai Nortye Earnings release: Q2 2026 - Filings
- 13 days ago - Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress - GlobeNewsWire
- 24 days ago - Adlai Nortye submits clinical trial notification to Australia TGA for AN4035 - TheFly
- 24 days ago - Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia - GlobeNewsWire
- 6 weeks ago - Adlai Nortye doses first patient in AN9025 trial - TheFly
- 6 weeks ago - Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 - GlobeNewsWire
- 6 weeks ago - Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists - GlobeNewsWire
- 2 months ago - Cantor starts Adlai Nortye at Overweight, sees 180% upside - TheFly